David Goeddel, PhD
Dr. Goeddel was the first scientist at Genentech and his pioneering work in gene cloning and expression of human proteins was the basis for five marketed therapeutics, including human insulin, human growth hormone, interferon-alpha, interferon-gamma, and tissue plasminogen activator. Dr. Goeddel co-founded Tularik and served as its head of research and chief executive officer until Tularik was acquired by Amgen. He serves on the Board of Directors of NGM Biopharmaceuticals, Peloton Therapeutics, FLX Bio, Surrozen, and Tenaya Therapeutics, and on the Scientific Advisory Boards of NGM Biopharmaceuticals, Peloton Therapeutics, and FLX Bio. Dr. Goeddel has received numerous scientific awards including the Scheele Medal, the Eli Lilly Award in Biological Chemistry, the Jacob Heskel Gabbay Award, the Howley Prize for Arthritis Research and the Warren Alpert Foundation Prize. He is a member of the National Academy of Sciences and the American Academy of Arts and Sciences. He holds a B.A. in Chemistry from UCSD and a Ph.D. in Biochemistry from the University of Colorado.